Weeks 14 0.25 mg Starter dose weekly Weeks 58 0.5 mg Increased weekly Weeks 916 1.0 mg Therapeutic dose Weeks 17+ 2.0 mg Maintenance dose Injection method Subcutaneous (under the skin) Frequency Once per week Provider check-ins Monthly dose adjustments Timeline 20 weeks to full dose What to expect Weight loss milestones and what patients typically experience at each phase
GIP receptors (GIPRs) are highly enriched in oligodendrocytes within the hypothalamic median eminence, and activation of these GIPRs regulates oligodendrocyte survival and myelin plasticity - this process enhances the entry of GLP-1R agonists into the brain via two key pathways: upregulating vascular endothelial growth factor A (VEGF-A) to increase blood-brain barrier permeability and facilitating GLP-1R agonist traversal of myelinated neuronal axons to target hypothalamic nuclei involved in energy homeostasis, including the ARC and PVN [81]
The sponsored ads that bombard my feeds, from telehealth companies like Willow, Noom, Fridays, EllieMD, and Midi Health, are technically promoting another product: compounded GLP-1 injections and tablets
An important point regarding application in practice includes various species (i.e., Tlak Gajger et al., 2018)
